Anna K. Osokina

Anna K. Osokina

Auto-generated profile, based on publicly available information

Anna K. Osokina

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAleksandra M. Shchinova
Aleksandra M. Shchinova
APAlexandra Potekhina
Alexandra Potekhina
YDYuliya A. Dolgusheva
Yuliya A. Dolgusheva
YEYuliya E. Efremova
Yuliya E. Efremova
AOAnna K. Osokina
Anna K. Osokina
ПВПотехина Александра Викторовна
Потехина Александра Викторовна
Background: The extent of myocardial damage largely determines both in-hospital and long-term mortality in patients with acute coronary syndrome. According to the literature, the in-hospital and long-term mortality rates in patients with unstable angina (UA) are lower than those in the patients with myocardial infarction (MI). Aim: To evaluate the in-hospital and long-term mortality rates and their predictors in patients undergoing in-patient treatment for acute coronary syndrome (MI and UA) in the regional cardiovascular center with the service territory of 1 million persons. Materials and methods: This retrospective registry study enrolled 1130 patients (715 [63.3%] men, 415 [36.7%] women) who were treated for UA and MI in the regional cardiovascular center in 2019. Based on the discharge diagnosis, the patients were divided into two groups: patients with MI (n = 766) and those with an UA episode (n = 364). The in-hospital and delayed mortality rates, as well as their predictors, were analyzed in both groups. The mean duration of the follow-up was 17.8 3.6 months. Results: The in-hospital mortality in patients with confirmed MI was 11.1% (85 patients) versus 0.27% (1 patient) in the UA patients (p 0.001). The independent predictors of in-hospital mortality in MI patients were a decreased left ventricular ejection fraction (LV EF) (odds ratio (OR) 0.9021, 95% confidence interval (CI) 0.82090.9914, p = 0.0324), chronic kidney disease C3a and above (OR 9.3205, 95% CI 2.670632.5283, p = 0.0005), and the extension of coronary involvement at coronary angiography (OR 1.3526, 95% CI 1.06670.0127, p = 0.0127). The long-term mortality in MI patients was 10.4% (72 patients) with no significant difference from that in UA patients (9.9%, 36 patients, p = 0.76). The independent predictors of long-term mortality after MI were older age (OR 1.12, 95% CI 1.011.22, p = 0.0052), chronic kidney disease C3a and above (OR 2.3375, 95% CI 1.13924.7963, p = 0.0206), decreased EF (OR 0.8895, 95% CI 0.730.99, p = 0.0364), atrial fibrillation on admission (OR 3.1462, 95% CI 1.35107.3268, p = 0.0079), and diabetes mellitus (OR 2.3163, 95% CI 1.25524.2744, p = 0.0072). In the UA patients, the predictors of the long-term mortality were a decrease in LV EF (OR 0.9139, 95% CI 0.86830.9619, p = 0.0006) and in blood hemoglobin level (OR 0.9729, 95% CI 0.95440.9917, p = 0.0050). Conclusion: The in-hospital mortality in UA patients is lower than that in MI patients, with comparable long-term mortality. This indicates the need of active follow-up of the patients with past UA, irrespective of the endovascular assessment and intervention.

5 December 2023 in Kardiologiia
Verified
Journal Article
Open access
PDF file
KBK. S. Benimetskaya
K. S. Benimetskaya
SPS. I. Provatorov
S. I. Provatorov
Marat EzhovMarat Ezhov
Marat Ezhov
YKY. S. Krivosheev
Y. S. Krivosheev
AGA. D. Gavrilko
A. D. Gavrilko
Denis LosikDenis Losik
Denis Losik
Aim To evaluate prescription of lipid-lowering and antithrombotic therapy in clinical practice and to compare differences in recommendations using the clinical decision support service (CDSS). Material and methods Electronic medical records (EMR) of 300 patients from the Chazov National Medical Research Center of Cardiology, as well as from medical organizations controlled by the Department of Health of the Lipetsk Region and the Ministry of Health of the Voronezh Region, were analyzed for the period of August - December 2022, during the pilot implementation of CDSS. Retrospective information about the prescription of lipid-lowering and antithrombotic therapy from the EMR was compared with the CDSS guidelines under the expert supervision based on digitized clinical and laboratory profiles of patients. The study primary endpoint was a change in the initially prescribed lipid-lowering and / or antithrombotic therapy as per CDSS guidelines. Results Overall 292 patients were included in the final analysis; 46 (15.7 %) were from the primary prevention group and 246 (84.3 %) from the secondary prevention group. In group 1, the lipid-lowering therapy recommended by the CDSS differed by 50 % (p<0.001) from the baseline therapy recorded in the EMR. In the secondary prevention group, 78.9 % (p<0.001) differences were found in the lipid-lowering therapy recommended in the CDSS guidelines compared to the prescriptions in the EMR. In 76.8 % (p<0.001) of patients, antithrombotic therapy was significantly different from the baseline therapy in the EMR. Conclusion The use of CDSS may improve the practice of choosing lipid-lowering and antithrombotic therapy for prevention of cardiovascular complications.

15 April 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AOAnna K. Osokina
Anna K. Osokina
OROleg V. Rodnenkov
Oleg V. Rodnenkov
TMTamila V. Martynyuk
Tamila V. Martynyuk
The article describes the historical aspects of the discovery of the pulmonary circulation and the study of pulmonary hypertension (PH) as a pathophysiological condition with a key hemodynamic characteristic – an increase in pressure in the pulmonary artery. The complexity of PH treatment is due to the association with various cardiovascular and respiratory diseases, which requires a multifaceted holistic interdisciplinary approach with the active participation of the physician and the patient. Currently, the guide for successful clinical practice are clinical guidelines covering the full range of diagnostic and therapeutic measures for various groups of PH. The development of guidelines is the result of a long way of studying morphology, pathophysiology, creating and researching of pathogenetic medical drugs, clinical observation of patients in the framework of studies and registries.

9 February 2022 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ASA. M. Shchinova
A. M. Shchinova
AOA. K. Osokina
A. K. Osokina
APAlexandra Potekhina
Alexandra Potekhina
ISI. I. Shestova
I. I. Shestova
AFAnastasiia Yu. Filatova
Anastasiia Yu. Filatova
SPS. I. Provatorov
S. I. Provatorov
Aim. To compare the prevalence of coronary atherosclerosis in patients after coronary stenting (CS) receiving outpatient and remote cardiology follow-up during a one-year study.Material and methods. We enrolled 279 patients aged 61,5±9,5 years with class ≥II stable angina or silent ischemia after CS. Three groups were formed: group 1 (n=96) — outpatient visits before CS, 1, 3, 6 and 12 months after CS. Group 2 (n=95) — remote monitoring: patients were followed up by a primary care physician with the involvement of a cardiologist via remote communication (e-mail, telephone, Skype) 1, 3, 6 and 12 months after CS. Group 3 (n=88) were followed up by a primary care physician and contacted with the study coordinator before and 12 months after CS. After 12 months, all patients underwent stress-induced myocardial ischemia testing. In case of a positive or uncertain test result, coronary angiography (CA) was performed.Results. Stress-induced myocardial ischemia 12 months after CS was verified in 58 patients (21%): 19 patients (19,8%) — group 1; 9 patients (9,5%) — group 2; 30 patients (34,1%) — group 3 (p<0,05). Repeat CA was performed in 96 patients (34,4% of the total number of patients). Restenosis was detected in 8 (2,9%) patients, coronary atherosclerosis progression — in 38 (13,6%), combination of restenosis and atherosclerosis progression — in 4 (1,4%) patients. Coronary atherosclerosis progression was significantly more frequent in group 3: 10,4%, 9,5% and 21,6% in groups 1, 2 and 3, respectively (p<0,05). The incidence of stent restenosis was comparable: 2,1%, 3,2% and 3,5% in groups 1, 2, and 3, respectively.Conclusion. Coronary atherosclerosis progression was the main reason for repeated revascularizations 12 months after the CS. Outpatient and remote cardiology follow-up is associated with a lower incidence of coronary atherosclerosis progression and repeated CA during 12-month follow-up after CS.

10 January 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
AFAnastasiia Yu. Filatova
Anastasiia Yu. Filatova
AOAnna K. Osokina
Anna K. Osokina
APAlexandra Potekhina
Alexandra Potekhina
IRIvan V. Romasov
Ivan V. Romasov
TKTatiana I. Kotkina
Tatiana I. Kotkina
АИАрефьева Татьяна Игоревна
Арефьева Татьяна Игоревна
Aim. Coronary stenting is the evidence-based treatment approach of stable angina. The objective was to determine the incidence of restenosis or atherosclerosis progression which led to the need for coronary angiography according to a single center registry data. Materials and methods. The procedure and clinical data of 3732 (2897 males) consecutive stable coronary artery disease patients undergoing coronary stenting, over five years between March 2010 and September 2014, were subject of this study. Over the next 4 years, 1487 (1173 males) patients were re-evaluated due to angina reoccurrence. 699 patients demonstrated the indications for coronary angiography. Results. The restenosis of the previously stented segment was detected in 84 (12%) cases, the progression of coronary atherosclerosis in 306 (44%), the combination of restenosis and atherosclerosis progression in 63 (9%), and the absence of these complications in 245 (35%) cases. The progression of coronary atherosclerosis was the leading indication for the repeat angiography and revascularization (44 and 58%, respectively); p0.05. The basal level of hsCRP2 mg/l had a prognostic significance for the development of combined event (the restenosis and atherosclerosis progression): AUC 0.65 (0.500.75), OR 3.0 (1.17.9), p0.05. Conclusion. The progression of coronary atherosclerosis was the leading indication for the repeat angiography and repeat revascularization during 2 years after coronary stenting. The hsCRP level 2 mg/l at baseline had a prognostic significance for the development of restenosis in previously stented segment and coronary atherosclerosis progression.

12 August 2022 in Medical and Social Expert Evaluation and Rehabilitation
Verified
Journal Article
Open access
PDF file
AOAnna K. Osokina
Anna K. Osokina
ASAleksandra M. Shchinova
Aleksandra M. Shchinova
APAlexandra Potekhina
Alexandra Potekhina
AFAnastasiia Yu. Filatova
Anastasiia Yu. Filatova
ESEvgeny V. Sorokin
Evgeny V. Sorokin
ГБГорнякова Наталья Бадриевна
Горнякова Наталья Бадриевна
BACKGROUND: Adherence to drug therapy in patients with coronary artery disease is quite low nowadays, both in patients with myocardial infarction and in patients with chronic forms of coronary artery disease. AIMS: of our work was to assess adherence to drug therapy (aspirin and statins) and control of risk factors for coronary artery disease in patients undergoing coronary stenting 12 months after endovascular treatment. MATERIALS AND METHODS: The study included 279 patients, of whom 3 groups were formed. Patients of group 1 (n=96) personally visited the National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, adherence to the prescribed therapy and its effectiveness were assessed during the examination by a cardiologist, and if necessary, it was corrected. Patients of group 2 (n=95) contacted the study coordinator remotely. Patients of group 3 (n=88) were monitored by a general practitioner and visited a cardiologist at the National Medical Research Center of Cardiology according to the decision of the general practitioner. RESULTS: At baseline, adherence to therapy in all groups was low and did not differ significantly between groups. 12 months after stenting, groups 1 and 2 showed a significant increase in the number of highly adherent individuals (from 17 to 33 and from 13 to 42, respectively, p 0.05), as well as a significant decrease in the number of individuals with low adherence to treatment (from 63 to 42 and from 67 to 36, respectively, p 0.05). The adherence to antiplatelet drugs was higher than to statins: 57.9% of people reduced the dose or stopped taking statins. After the follow-up time, there was a significant decrease in systolic blood pressure in groups 1 and 2 and a significant decrease in diastolic blood pressure in group 2. In group 2, a significant decrease in the number of smokers was noted: from 46.3 to 31.6% of the total number of patients in the group (p 0.05). CONCLUSION: Active monitoring of patients by a cardiologist both during the visit and remotely contributes to an increase in adherence to drug therapy and improves control of risk factors for coronary artery disease.